TechGuru,

Thank you for this analysis. Couple of questions:

1. If CYDY does in fact slow or stop metastisis in many or all types of cancer, doesn't it stand to reason it would move toward or to the top of this list?

2. In your calculation you are using a 12.9 multiple. If this is the average life of the patent, wouldn't the multiple need to be discounted from this?

I haven't done nearly as in depth calculations as you, but it seems to me multiple would be 4 or 5x, but revenue potential could be significantly higher